©2018 by May Khanna. Proudly created with Wix.com

Funded Projects

NIH T32 Funding

Postdoctoral Fellow:  Niloufar Mollasaheli (Biological Chemistry Program, UA)

Postdoctoral Fellow:  Jonathan Sanchez Lares (collaboration with Dr. Salvo Oddo in the Neurodegenerative Disease Research Center, ASU)

06/30/2019 - 06/30/2020

Arizona Alzheimer's Consortium

“Defining the effect of a rare CD44 mutation in Alzheimer's Disease”

PI:  May Khanna

Co-I:  Matt Heuntelman

This pilot project seeks to establish the role of a rare mutation in AD.

05/01/2019 - 01/31/2024

National Institute on Aging

“Identifying the role of RIPK1 in Alzheimer's disease”

PI:  Salvatore Oddo (Arizona State University)

Co-I:  May Khanna

This grant will bring a new post-doc into the May Khanna lab to work on RIPK1 in collaboration with the Oddo lab.

07/2018 - 07/2019

Arizona Alzheimer’s Disease Core Center (ADCC) Pilot Grant

“Identify small molecule inhibitors to block protein-protein interactions from AMP-AD targets”

PI:  May Khanna

The Arizona Alzheimer's Consortium (AAC) is the nation's leading model of statewide collaboration in Alzheimer's disease research. Established in 1998, the Consortium capitalizes on its participating institutions' complementary strengths in brain imaging computer science, genomics, the basic and cognitive neurosciences and clinical and neuropathology research to promote the scientific understanding and early detection of Alzheimer's disease and find effective disease-stopping and prevention therapies. It also seeks to educate Arizona residents about Alzheimer's disease, research progress in the state and the resources needed to help patients, families and professionals manage the disease. The Consortium is determined to find effective treatments to halt the progression and prevent the onset of Alzheimer's disease in the next 12 years.

05/2018 - 05/2020 (Renewed)

NIH Postdoctoral Supplement from AMP-AD for Sage Target Discovery

“Identify small molecule inhibitors to block protein-protein interactions from AMP-AD targets”

Collaboration with Lara Mangravite (Sage Bionetworks), Opher Gileadi (Oxford, UK) and Paul Brennan (Oxford, UK).

The central goal of the Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD) Target Discovery and Preclinical Validation Project is to shorten the time between the discovery of potential drug targets and the development of new drugs for Alzheimer’s disease treatment and prevention, by integrating the analyses of large-scale molecular data from human brain samples with network modeling approaches and experimental validation.

03/2018 - 03/2020

DOD ALS Funding

“Small Molecules Targeting TDP-43-RNA Interactions in ALS”

PI:  Daniella Zarnescu

Co-PI:  May Khanna,  Vijay Gokhale, Rita Sattler

The ALSRP is guided by a vision to improve treatment and find a cure for ALS. Through its award mechanisms and funding recommendations, the ALSRP specifically supports innovative preclinical research targeting development of new therapeutics for ALS.

03/2017 - 03/2020

Arizona Department of Health Services Arizona Biomedical Research (ABRC) New Investigator Award

“Small Molecule Restoration of Translation Dysregulation in ALS”

PI:  May Khanna

The Arizona Disease Control Research Commission was established by the Arizona Legislature and signed into law by Governor Bruce Babbitt in 1994. ADCRC’s mission was to fund investigators focused on diseases and health issues that impact the residents of Arizona. In 2005, the Arizona Disease Control Research Commission changed its name to the Arizona Biomedical Research Commission. 

09/2015 - 05/2020

NIH/NINDs Funding

“Translation dysregulation in neurodegeneration”

PI:  Daniella Zarnescu

Collaborator:  May Khanna